The European Commission has approved AstraZeneca and MSD's Lynparza, or olaparib, as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The decision was backed by data from a late-stage study in which treatment with Lynparza showed a clinically meaningful result of 70% risk reduction for disease progression or death in patients with the condition.
EU OKs AZ, MSD's BRCA-mutated advanced ovarian cancer drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.